WASHINGTON, Sept. 17, 2003 (PRIMEZONE) -- Growth Report, an independent investment newsletter service for individual investors that has delivered returns of 60% in the first eight months of 2003, today announced the addition of Curative Health Services, Inc. (Nasdaq:CURE) to its stock portfolio.
Curative operates two business units that service patients experiencing serious or chronic medical conditions. At the end of 2002, the company had contracts with 283 payors and 16 retail pharmacies. With over fourteen years of medical and pharmacy services management experience, Curative has helped people with Hemophilia and many other critical care ailments, live fuller lives.
Growth Report added Curative to the newsletter's model portfolio on September 9th, at a price of $17.96 per share. This initial research report is available on the Growth Report web site free of charge to paid and trial subscribers at http://www.growthreport.com/
The report discusses:
-- Curative's Specialty Pharmacy Services business unit that sells
pharmaceuticals to patients with chronic illnesses
-- Curative's Specialty Health Services business unit that provides
wound care management services for chronic wound patients
-- The company's impressive record in providing medical care and
treatment for wound patients recommended for unnecessary
amputation
-- Curative's recent acquisition expansion strategy
-- Historical financial results and projections for the coming
quarter and fiscal year 2003
-- Growth Report's outlook for the company and the stock price in
the coming quarters
In the September 9th issue of Growth Report, Editor Ian Wyatt wrote, "We believe that Curative is operating in an interesting and worthwhile space and providing highly demanded services to critical care patients. The company has proven its ability to consistently deliver both revenue and earnings growth north of 20%, an achievement few companies can claim. New acquisitions and an effective organic growth strategy give credence to our positive outlook for Curative Health. Further, shares of Curative look relatively inexpensive. For a company with a long-term projected growth rate of 25%, and shares trading at around 12-times 2003 consensus EPS estimates of $1.48, the company has a price to earnings ratio that is less than one half its growth rate."
Growth Report's stock portfolio returned 40% in 2002, and is up another 60% in the first eight months of 2003 by taking long-term positions in fundamentally strong growth stocks. This investment approach has yielded consistently strong returns for subscribers of the newsletter service.
Individual investors who are interested in signing up for a 30-day free trial to Growth Report will receive this report on Curative Health Services, plus two free Special Reports:
-- "10 Great Growth Stocks Every Investor Should Own Now"
-- "Not So Generic Returns -- Investing in Generic and Specialty
Pharmaceuticals"
Free trial subscribers also receive two issues per week by e-mail, one issue per month in print, access to over one year of archived articles, and past and future Special Reports. To start a free 30-day trial subscription, click here: https://www.bizfn.com/index.cfm?Page=pubs&pubs=2&r=pr8
About Growth Report
Growth Report is a leading independent investment newsletter service published by Business Financial Publishing, LLC. Growth Report is entirely independent, and dedicated to uncovering stocks that will deliver the greatest return to subscribers. Two weekly issues delivered by e-mail and on the web provide subscribers with regular updates on the latest news and changes to the portfolio, while a monthly print edition provides in depth articles in an easy to read format.
Disclaimer
Growth Report is neither a registered investment advisor nor a broker / dealer. Readers are advised that the publication is issued solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. No information provided herein or elsewhere from Growth Report constitutes a recommendation by Growth Report to buy, sell or hold any security. We encourage you to consult with independent financial advisors with respect to any investment in the securities mentioned herein.